Genmab A/S Stock

Genmab A/S EBIT Growth

The Year-over-Year EBIT Growth of Genmab A/S (GMAB.CO) as of Aug 16, 2026 is 23.50 %. In the previous year, Year-over-Year EBIT Growth was 32.94 % — a change of -28.65% (lower).

EBIT Growth

23.50 %

YoY

-28.65%

Last updated:

Year-over-Year EBIT Growth of Genmab A/S is 2026 23.50 % . Year-over-Year EBIT Growth of Genmab A/S was 2025 32.94 % . It decreases by -28.65% lower compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Year-over-Year EBIT Growth of Genmab A/S is 23.50 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Genmab A/S historically and in real time.

Access this data via the Eulerpool API

Growth — Genmab A/S

All Key Metrics — Genmab A/S